Evidence map›Paper›PMID 34681929›Full record

ArticleInternational journal of molecular sciences2021

HIF-Overexpression and Pro-Inflammatory Priming in Human Mesenchymal Stromal Cells Improves the Healing Properties of Extracellular Vesicles in Experimental Crohn's Disease.

Marta Gómez-Ferrer, Elena Amaro-Prellezo, Akaitz Dorronsoro, Rafael Sánchez-Sánchez, Ángeles Vicente, Jesús Cosín-Roger, María Dolores Barrachina, María Carmen Baquero, Jaris Valencia, Pilar Sepúlveda

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Marta Gómez-FerrerRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.ORCID 0000-0002-7671-4734
Elena Amaro-PrellezoRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Akaitz DorronsoroRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.ORCID 0000-0001-6141-8484
Rafael Sánchez-SánchezRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Ángeles VicenteSección Departamental de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-9456-5541
Jesús Cosín-RogerHospital Dr Peset, FISABIO, 46017 Valencia, Spain.
María Dolores BarrachinaDepartamento de Farmacología, Facultad de Medicina, University of Valencia, 46010 Valencia, Spain.
María Carmen BaqueroServicio de Cirugía Oral y Maxilofacial, Hospital Universitari I Politècnic La Fe, Avenida Fernando Abril Martorell, 106, 46026 Valencia, Spain.
Jaris ValenciaSección Departamental de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-3112-5944
Pilar SepúlvedaRegenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.ORCID 0000-0001-6071-7431
Instituto de Investigación Sanitaria La Fe · ESUniversidad Complutense de Madrid · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESHospital Universitari i Politècnic La Fe · ESUniversitat de València · ES

Funding

Agencia Valenciana de Innovación INNVA1/2021/29Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital ACIF/2018/254, ACIF/2017/318, ACIF/2020/352 and BEFPI/2020/042European Union through the Operational Program of the European Regional Development Fund (FEDER) of the Valencian Community 2014-2020Instituto de Salud Carlos III PI19/00245, RD16/0011/0002 and RD16/0011/0004
6 · The paper itself

Abstract

Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) have therapeutic potential in the treatment of several immune disorders, including ulcerative colitis, owing to their regenerative and immunosuppressive properties. We recently showed that MSCs engineered to overexpress hypoxia-inducible factor 1-alpha and telomerase (MSC-T-HIF) and conditioned with pro-inflammatory stimuli release EVs (EV

Indexed as

AnimalsCell AdhesionCell PolarityCrohn DiseaseCytokinesDisease Models, AnimalExtracellular VesiclesHumansHuman Umbilical Vein Endothelial CellsHypoxia-Inducible Factor 1, alpha SubunitMaleMesenchymal Stem CellsMiceTelomeraseTrinitrobenzenesulfonic AcidYoung AdultCytokinesHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitTelomeraseTrinitrobenzenesulfonic AcidCrohn’s diseaseextracellular vesicleshypoxia-inducible factor 1-alphaimmunomodulationmacrophage repolarizationmesenchymal stromal cells

Identifiers

PMID34681929
PMCPMC8540690
OpenAlexW3207344151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.